SPRY shows severe balance sheet deterioration with stockholders' equity declining by more than half while current liabilities substantially increased, despite reduced R&D spending.
The dramatic erosion in stockholders' equity combined with meaningfully higher current liabilities suggests significant cash burn and potential liquidity concerns for this biotech company. While R&D expenses were reduced by nearly one-third, this cost-cutting appears insufficient to offset the underlying financial deterioration, raising questions about the company's ability to fund its commercial operations and neffy product launch.
SPRY's financial position deteriorated markedly, with stockholders' equity falling from $256.8M to $114.3M while current liabilities grew substantially from $23.4M to $39.1M. Cash and current assets both declined modestly, while the company reduced R&D spending by approximately one-third to $13.2M and cut capital expenditures by 40%. The overall picture signals a company under significant financial stress, burning through equity while taking on more short-term obligations despite cost-reduction efforts.
Current liabilities surged 67% — significant near-term obligations; verify ability to meet short-term debt.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Capex reduced 39.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
R&D spending cut 32.7% — could signal cost discipline or concerning reduction in innovation investment.
Cash decreased 18.7% — monitor burn rate and upcoming capital needs.
Current assets declined 14.8% — monitor working capital adequacy and short-term liquidity.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →